Pirenzepine in the treatment of gastric ulcer. A double-blind short-term clinical trial.
The effectiveness of pirenzepine in the treatment of gastric ulcer was assessed in a double-blind 6 weeks' clinical trial in comparison with placebo. After 2 weeks of treatment 1 patient in each group showed a complete healing of gastric ulcer. After 6 weeks of treatment 9 out of 10 patients in the pirenzepine group (90%) and 4 out of 10 patients in the placebo group (40%) healed (P less than 0.05). The relief of ulcer symptoms was significantly better in the pirenzepine group than in the placebo group. From the second week on, the pirenzepine-treated patients stopped taking antacid while placebo-treated patients went on taking it (P less than 0.02). The results of this study demonstrated that pirenzepine promotes gastric ulcer healing and induces a rapid regression of ulcer symptoms.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001570:Benzodiazepinones / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010890:Pirenzepine; D010919:Placebos; D011897:Random Allocation; D013276:Stomach Ulcer / Q000188:drug therapy*
D000897:Anti-Ulcer Agents; D001570:Benzodiazepinones; D010879:Piperazines; D010919:Placebos; D010890:Pirenzepine